Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

41. Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. (Abstract)

Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. Robotic-assisted laparoscopic prostatectomy (RALP) is widely used to surgically treat clinically localized prostate cancer. It is typically performed using an approach (standard RALP) that mimics open retropubic prostatectomy by dissecting the so-called space of Retzius anterior to the bladder. An alternative, Retzius-sparing (or posterior approach) RALP (RS (...) more men per 1000 (29 fewer to 39 more) reporting continence recovery.  We are very uncertain about the effect of RS-RALP on potency recovery 12 months after surgery (RR 0.98, 95% CI 0.54 to 1.80; studies = 1; participants = 55; very low-certainty evidence).  RS-RALP may increase PSMs (RR 1.95, 95% CI 1.19 to 3.20; I2 = 0%; studies = 3; participants = 308; low-certainty evidence) indicating a higher risk for prostate cancer recurrence. Assuming 129 per 1000 men undergoing standard RALP have

2020 Cochrane

42. The CYP19A1 (TTTA)n Repeat Polymorphism, but not Arg264Cys Polymorphism, May Affect the Risk of Prostate Cancer: Evidence from a Meta-Analysis Full Text available with Trip Pro

The CYP19A1 (TTTA)n Repeat Polymorphism, but not Arg264Cys Polymorphism, May Affect the Risk of Prostate Cancer: Evidence from a Meta-Analysis The CYP19A1 (TTTA)n Repeat Polymorphism, but not Arg264Cys Polymorphism, May Affect the Risk of Prostate Cancer: Evidence from a Meta-Analysis | Research Square Browse Tools & Services Your Cart This preprint is under consideration at World Journal of Surgical Oncology . A preprint is a preliminary version of a manuscript that has not completed peer (...) review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research The CYP19A1 (TTTA)n Repeat Polymorphism, but not Arg264Cys Polymorphism, May Affect the Risk of Prostate Cancer: Evidence from a Meta-Analysis Lei Guo, Yanan Liu, Lijun Liu, Shixiu Shao, Yanwei Cao, Jiaming

2020 Research Square

43. Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG

Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2020 Canadian Urological Association

44. Managing prostate cancer during COVID-19 : CUOG/CUA

Managing prostate cancer during COVID-19 : CUOG/CUA Flipbook To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2020 Canadian Urological Association

45. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials Full Text available with Trip Pro

Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials - PubMed This site needs JavaScript to work properly. Please enable (...) Actions . 2020 Jun 27;S0302-2838(20)30429-2. doi: 10.1016/j.eururo.2020.06.002. Online ahead of print. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials , , , , , , , , , Affiliations Expand Affiliations 1 Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; The National Center for Diabetes

2020 EvidenceUpdates

46. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline - American Urological Association advertisement Toggle navigation About Us AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL (...) Cancer: AUA/ASTRO/SUO Guideline [pdf] [pdf] Panel Members William Lowrance, MD, MPH, MBA; Rodney Breau, MSc, MD, FRCSC; Roger Chou, MD; Brian F. Chapin, MD; Tony Crispino; Robert Dreicer, MD, MS, MACP, FASCO; David F. Jarrard, MD; Adam S. Kibel, MD; Todd M. Morgan, MD; Alicia K. Morgans, MD, MPH; William K. Oh, MD; Matthew Resnick, MD, MPH, MMHC; Anthony Zietman, MD; Michael S. Cookson, MD, MMHC Executive Summary Purpose The management of advanced prostate cancer is rapidly evolving. Clinicians

2020 American Urological Association

47. Prostate cancer: NCCP advice for Medical Professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak

Prostate cancer: NCCP advice for Medical Professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak Version: 2 Department: NCCP Radiation Oncology Working Group Update date: 30/06/2020 Code: RO_COVID19_7 Page 1 of 3 NCCP advice for medical professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) pandemic This document (...) ) - https://www.gov.ie/en/campaigns/c36c85-covid-19- coronavirus/ ? Ireland’s National Action Plan in response to COVID-19 (Coronavirus) - https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/ 2 Purpose The purpose of this guidance document is to provide guidance to medical professionals on the management of patients undergoing Prostate Cancer Radiotherapy during the COVID-19 pandemic. In general prostate cancers are either low risk and delaying treatment does not impact outcomes or patients

2020 Health Service Executive (Ireland) - Clinical Guidelines

48. NCCP guidance for Medical Professionals on the management of patients with Prostate Cancer in response to the current novel coronavirus (COVID-19) outbreak

NCCP guidance for Medical Professionals on the management of patients with Prostate Cancer in response to the current novel coronavirus (COVID-19) outbreak Version: 4 Department: Prostate Guideline Development Group/Leads Group Update date: 11/06/2020 Revision date: Page 1 of 4 NCCP guidance for Medical Professionals on the management of patients with Prostate Cancer in response to the current novel coronavirus (COVID-19) pandemic This document relates to patients who do not have COVID-19 (...) - coronavirus/ ? Ireland’s National Action Plan in response to COVID-19 (Coronavirus) - https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/ Version: 4 Department: Prostate Guideline Development Group/Leads Group Update date: 11/06/2020 Revision date: Page 2 of 4 2 Purpose The purpose of this guidance document is to provide guidance to medical professionals on the management of patients referred to urology clinics, patients awaiting biopsy tests and patients diagnosed with prostate cancer during

2020 Health Service Executive (Ireland) - Clinical Guidelines

49. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT Full Text available with Trip Pro

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK 7 Department of Urology and Surgery, Western General Hospital, University of Edinburgh, Edinburgh, UK 8 Academic Urology Unit, University of Sheffield, Sheffield, UK 9 Department of Urology, Addenbrooke’s Hospital, Cambridge, UK 10 Department of Urology, Queen Elizabeth Hospital, Birmingham, UK 11 Department of Urology, Southmead Hospital and Bristol Urological Institute, Bristol, UK 12 Department of Urology, Cardiff and Vale

2020 NIHR HTA programme

50. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of Prostate Cancer: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of Prostate Cancer: A Systematic Review and Meta-Analysis Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of Prostate Cancer: A Systematic Review and Meta-Analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review (...) at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Original article Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of Prostate Cancer: A Systematic Review and Meta-Analysis Sungmin Woo, Soleen Ghafoor, Anton S. Becker, Sangwon Han

2020 Research Square

51. Osteopontin as a novel biomarker for the prognosis and clinical pathology of prostate cancer: a systematic review and meta-analysis Full Text available with Trip Pro

Osteopontin as a novel biomarker for the prognosis and clinical pathology of prostate cancer: a systematic review and meta-analysis Osteopontin as a novel biomarker for the prognosis and clinical pathology of prostate cancer: a systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints (...) . The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Primary research Osteopontin as a novel biomarker for the prognosis and clinical pathology of prostate cancer: a systematic review and meta-analysis Anze Yu, Kai Xie, Changsheng Xing, Qilin Qin, Longfei Liu, Xiongbing Zu Anze Yu Xiangya Hospital Central South University Corresponding Author ORCiD: https

2020 Research Square

52. The diagnostic value of RASSF1A promoter methylation in prostate cancer: A systematic review and meta-analysis Full Text available with Trip Pro

The diagnostic value of RASSF1A promoter methylation in prostate cancer: A systematic review and meta-analysis The diagnostic value of RASSF1A promoter methylation in prostate cancer: A systematic review and meta-analysis | bioRxiv Search for this keyword New Results The diagnostic value of RASSF1A promoter methylation in prostate cancer: A systematic review and meta-analysis Su-Liang Li , Ye-Xing Li , Yun Ye , Xiao-Hua Yuan , Jian-Jun Wang , Hong-Lin Yan doi: https://doi.org/10.1101 (...) . A systematic review was conducted to explore the diagnostic value of RASSF1A promoter methylation in prostate cancer. Methods A comprehensive search of the literature in the PubMed, Medline, Cochrane Library, Embase and ISI Web of Science databases up to May 21, 2020 was performed. STATA software version 12.0 and Meta-disc version 1.4 were used to analyze the data. Results The pooled sensitivity was 0.64 (95% CI 0.61–0.66), the pooled specificity was 0.80 (95% CI 0.77–0.83), the PLR was 3.82 (95% CI 1.96

2020 Cold Spring Harbor Laboratory

53. The Awareness of Women on Prostate Cancer: A Mixed-Methods Systematic Review Protocol Full Text available with Trip Pro

The Awareness of Women on Prostate Cancer: A Mixed-Methods Systematic Review Protocol The Awareness of Women on Prostate Cancer: A Mixed-Methods Systematic Review Protocol | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should (...) not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Protocol The Awareness of Women on Prostate Cancer: A Mixed-Methods Systematic Review Protocol Ebenezer Wiafe, Kofi Boamah Mensah, Adwoa Bemah Boamah Mensah, Varsha Bangalee, Frasia Oosthuizen Ebenezer Wiafe University of KwaZulu-Natal College of Health Sciences Corresponding Author ORCiD: https://orcid.org/0000-0002-0496-5737 Kofi Boamah Mensah Kwame Nkrumah

2020 Research Square

54. Darolutamide (Nubeqa) - non-metastatic castration-resistant prostate cancer (nmCRPC)

Darolutamide (Nubeqa) - non-metastatic castration-resistant prostate cancer (nmCRPC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written

2020 Health Canada - Drug and Health Product Register

55. TULSA-PRO system - prostate cancer

TULSA-PRO system - prostate cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for the is located below. Updated: The following table describes post

2020 Health Canada - Drug and Health Product Register

56. Clinical Practice Guidelines – Prostate Cancer

Clinical Practice Guidelines – Prostate Cancer Prostate Cancer | ESMO Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. MINIMAL Requirements: , , , , , Search Clinical Practice Guidelines – Prostate Cancer Published in 2020 – Ann Oncol (2020) Authors: C. Parker, E. Castro, K. Fizazi, A. Heidenreich, P. Ost, G. Procopio, B. Tombal & S. Gillessen Prostate cancer is reported as the second most common cancer in men. The updated (...) ESMO Clinical Practice Guidelines on prostate cancer provide information on the current management of prostate cancer including recommendations for screening and diagnosis, along with stage-matched therapeutic strategies. Related items Read full article Legal Useful links Subscribe to ESMO newsletters Receive information and updates on ESMO’s scientific and educational resources, events, members activities. To sign up for ESMO newsletters, and select the newsletters you’d like to receive. ESMO

2020 European Society for Medical Oncology

57. Prostate cancer screening with the PSA test

Prostate cancer screening with the PSA test 1 Translation of Chapters 1 to 6 of the final report S19-01 Prostatakrebsscreening mittels PSA-Test (Version 1.0; Status: 24 April 2020 [German original], 10 June 2020 [English translation]). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission (...) No. S19-01 Prostate cancer screening with a PSA test 1 Extract of final report S19-01 Version 1.0 PSA screening 24 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Prostate cancer screening with a PSA test Commissioning agency: Federal Joint Committee Commission awarded on: 18 April 2019 Internal Commission No.: S19-01 Address of publisher: Institut für Qualität und Wirtschaftlichkeit

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

58. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials

Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 May 12;JCO1903217. doi: 10.1200/JCO.19.03217. Online ahead of print. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials

2020 EvidenceUpdates

60. PIONEER’s systematic review of outcomes in RCTs of men with non-metastatic castration resistant prostate cancer: Is there a need for a core outcome set? Full Text available with Trip Pro

PIONEER’s systematic review of outcomes in RCTs of men with non-metastatic castration resistant prostate cancer: Is there a need for a core outcome set? Redirecting

2020 European Urology Open Science